"Iran Pharmaceuticals & Healthcare Report Q2 2014" Published
BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market in US dollar terms to contract sharply. On a positive note, improved international relations have reduced the political risk associated with operating in the market for multinational drugmakers.
View full press release